Riociguat in patients with respiratory disease and hypoxia – a proof-of-concept study

Trial Profile

Riociguat in patients with respiratory disease and hypoxia – a proof-of-concept study

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Riociguat (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Proof of concept; Therapeutic Use
  • Acronyms RIOPRED
  • Most Recent Events

    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society
    • 06 Apr 2017 Status changed from recruiting to completed.
    • 28 Jan 2016 Accrual to date is 81% according to United Kingdom Clinical Research Network record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top